Best Drug Manufacturers - General Stocks 2026

The major US-listed pharmaceutical stocks in 2026 include Eli Lilly (LLY), Johnson & Johnson (JNJ), Merck & Co. (MRK), AbbVie (ABBV), Pfizer (PFE), Bristol-Myers Squibb (BMY), Novartis (NVS), AstraZeneca (AZN), Novo Nordisk (NVO), and Roche (RHHBY). Eli Lilly has been the highest-return name due to GLP-1 dominance. Johnson & Johnson and AbbVie offer more defensive, diversified exposure. Merck combines current Keytruda dominance with patent-cliff risk.

Eli Lilly has become the largest pharmaceutical company by market capitalisation due to its dominance in the GLP-1 receptor agonist class through tirzepatide (marketed as Mounjaro for type 2 diabetes and Zepbound for obesity). GLP-1 sales have grown into the largest pharmaceutical product franchise globally. Supply has been the binding constraint on revenue growth; Lilly has invested over $30 billion in manufacturing capacity additions. Pipeline progression in obesity (orforglipron oral GLP-1, retatrutide GIP/GLP-1/glucagon triple agonist), Alzheimer's (Kisunla approval 2024), and other categories supports continued growth.

The Inflation Reduction Act of 2022 allows Medicare to negotiate prices on selected high-cost drugs after a market exclusivity period of nine years for small molecules and thirteen years for biologics. The first negotiated prices for ten drugs took effect January 1, 2026 — including Eliquis, Xarelto, Januvia, Jardiance, Imbruvica, Stelara, Farxiga, Entresto, Enbrel, and Fiasp/NovoLog. Subsequent negotiation rounds expand the number of drugs covered. Companies with concentrated franchises in negotiated drugs face material revenue impact.

Brand-name pharmaceutical sales typically decline 60-80% within one to three years of patent expiration as generic versions enter the market at significant discounts. For biologics, biosimilar competition produces slower but increasingly steep erosion — AbbVie's Humira lost meaningful share through 2023-2025 as multiple biosimilars launched. Patent cliffs are predictable but their impact on company value depends on the pace of biosimilar uptake and the strength of the replacement pipeline. Merck's Keytruda patent expiration starting in 2028 is the most-watched upcoming cliff in the industry.

Johnson & Johnson, Merck, AbbVie, Pfizer, Bristol-Myers Squibb, and Novartis all pay regular dividends. Johnson & Johnson is a dividend aristocrat with one of the longest payout-growth track records of any large company. AbbVie inherited Abbott Laboratories' dividend tradition following the 2013 spinoff. Eli Lilly pays a smaller dividend with a payout ratio reflecting reinvestment priorities. Check the live data in the table for current yields and growth rates.

GLP-1 receptor agonists have meaningful spillover effects across healthcare. Medical device companies focused on bariatric surgery and obesity-related interventions (Intuitive Surgical, ResMed for sleep apnea, dialysis providers for diabetic nephropathy) face long-term volume headwinds if GLP-1s reduce disease prevalence. CROs running cardiovascular and metabolic trials benefit from elevated GLP-1 development activity. Insurance plans face reimbursement decisions around expensive obesity treatment. Snack food and packaged food companies have flagged GLP-1 concerns in earnings calls, though empirical near-term impact has been modest.

No. Tickerplace does not rate Pfizer as a buy or sell. Pfizer is in a rebuilding phase following the post-pandemic revenue decline in Comirnaty (COVID vaccine) and Paxlovid (COVID therapeutic). The Seagen acquisition (completed December 2023, $43 billion) added a meaningful oncology platform with ADC technology. Pipeline progression and the success of Seagen integration determine whether published multiples re-rate versus peers. The stock trades at a meaningful discount to pharmaceutical peers reflecting near-term execution uncertainty. Cost reduction initiatives are progressing alongside pipeline rebuilding.